Dataset Information


IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.

ABSTRACT: Disease relapse or progression is a major cause of death following umbilical cord blood (UCB) transplantation (UCBT) in patients with high-risk, relapsed or refractory acute lymphoblastic leukemia (ALL). Adoptive transfer of donor-derived T cells modified to express a tumor-targeted chimeric antigen receptor (CAR) may eradicate persistent disease after transplantation. Such therapy has not been available to UCBT recipients, however, due to the low numbers of available UCB T cells and the limited capacity for ex vivo expansion of cytolytic cells. We have developed a novel strategy to expand UCB T cells to clinically relevant numbers in the context of exogenous cytokines. UCB-derived T cells cultured with interleukin (IL)-12 and IL-15 generated >150-fold expansion with a unique central memory/effector phenotype. Moreover, UCB T cells were modified to both express the CD19-specific CAR, 1928z, and secrete IL-12. 1928z/IL-12 UCB T cells retained a central memory-effector phenotype and had increased antitumor efficacy in vitro. Furthermore, adoptive transfer of 1928z/IL-12 UCB T cells resulted in significantly enhanced survival of CD19(+) tumor-bearing SCID-Beige mice. Clinical translation of CAR-modified UCB T cells could augment the graft-versus-leukemia effect after UCBT and thus further improve disease-free survival of transplant patients with B-cell ALL.


PROVIDER: S-EPMC5189717 | BioStudies | 2015-01-01

REPOSITORIES: biostudies

Similar Datasets

2006-01-01 | S-EPMC1895371 | BioStudies
2012-01-01 | S-EPMC3359735 | BioStudies
2013-01-01 | S-EPMC5554955 | BioStudies
2009-01-01 | S-EPMC2683970 | BioStudies
2008-01-01 | S-EPMC4539139 | BioStudies
2011-01-01 | S-EPMC3551618 | BioStudies
2012-01-01 | S-EPMC3327450 | BioStudies
2013-01-01 | S-EPMC3669363 | BioStudies
2014-01-01 | S-EPMC3913944 | BioStudies
2015-01-01 | S-EPMC7241296 | BioStudies